Bachem has announced plans to establish a new site in Switzerland. The first phase of this project involves an investment exceeding CHF500 million. The company expects production at the new facility to begin in 2030.
Bachem is planning to develop a new manufacturing site in Switzerland. The announcement details a significant initial investment for the project.
The first phase of the site will see spending that tops CHF500 million. This figure represents the budget allocated for the initial stage of the Swiss facility.
The investment for the first phase exceeds half a billion Swiss francs. The CHF500 million threshold indicates a substantial financial commitment from Bachem.
This spending is designated specifically for the first phase of the project. No information has been provided about potential future phases or additional costs.
Bachem expects production at the Swiss site to begin in 2030. The timeline sets a target for when the facility will become operational.
The 2030 date applies to the initial production output. The company has outlined this as the expected start of manufacturing activities.
The new site will be located in Switzerland. The specific location within the country has not been disclosed in the announcement.
The Swiss site is part of Bachem's broader manufacturing plans. The first phase investment of more than CHF500 million underscores the scale of the undertaking.
The first phase budget of over CHF500 million covers the initial development. This includes costs for construction, equipment, and other setup expenses.
Bachem has targeted 2030 for the start of production. The multi-year timeline suggests a complex development process for the Swiss site.
Related reading: Bachem Expects 35% to 40% Sales Growth in Local Currencies for 2026, Biopharma Hungry for GLP-1 Receptor Agonist Manufacturing Skills - Genetic Engineering and Biotechnology News, Novadose and Pure Pharmaceuticals Lead Peptide Science Advances, SG Bachem/Walporzheim U17 Squad Details for 2025-26 Season.